CORRECTION

Correction: NF- κ B Is Activated in CD4⁺ iNKT Cells by Sickle Cell Disease and Mediates Rapid Induction of Adenosine A_{2A} Receptors

The *PLOS ONE* Staff

The Competing Interests section is incorrect. The Competing Interests section should read: Joshua Field, M.D., M.S., Joel Linden, Ph.D. and David Nathan, M.D. each have consulting agreements with NKT Therapeutics, Inc. Joel Linden, Ph.D. is an inventor on a patent issued to the University of Virginia, which claims the use of adenosine A_{2A} agonists for the treatment of sickle cell disease; he owns shares in Adenosine Therapeutics LLC, which licensed this patent. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

Reference

1. Lin G, Field JJ, Yu JC, Ken R, Neuberger D, et al. (2013) NF- κ B Is Activated in CD4⁺ iNKT Cells by Sickle Cell Disease and Mediates Rapid Induction of Adenosine A_{2A} Receptors. PLoS ONE 8(10): e74664. doi:[10.1371/journal.pone.0074664](https://doi.org/10.1371/journal.pone.0074664) PMID: [24124453](https://pubmed.ncbi.nlm.nih.gov/24124453/)

OPEN ACCESS

Citation: The *PLOS ONE* Staff (2015) Correction: NF- κ B Is Activated in CD4⁺ iNKT Cells by Sickle Cell Disease and Mediates Rapid Induction of Adenosine A_{2A} Receptors. PLoS ONE 10(2): e0117760. doi:[10.1371/journal.pone.0117760](https://doi.org/10.1371/journal.pone.0117760)

Published: February 6, 2015

Copyright: © 2015 The PLOS ONE Staff. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.